Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Syndax Pharmaceuticals (NASDAQ:SNDX) in a research report report published on Friday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $37.00 target price on the stock.

Several other equities research analysts also recently weighed in on SNDX. HC Wainwright reiterated a buy rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Monday, June 17th. Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a buy rating in a research note on Wednesday, June 26th. Scotiabank cut Syndax Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, June 14th. Citigroup decreased their price target on Syndax Pharmaceuticals from $32.00 to $30.00 and set a buy rating for the company in a report on Thursday, May 9th. Finally, JPMorgan Chase & Co. reissued an overweight rating and issued a $34.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of Moderate Buy and an average price target of $34.77.

Syndax Pharmaceuticals Trading Up 4.9 %

Shares of NASDAQ SNDX opened at $21.53 on Friday. The stock has a market cap of $1.83 billion, a P/E ratio of -6.69 and a beta of 0.94. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.34. The stock has a 50 day moving average of $20.50 and a two-hundred day moving average of $21.54.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.11. During the same quarter last year, the firm earned ($0.59) earnings per share. As a group, research analysts predict that Syndax Pharmaceuticals will post -3.53 earnings per share for the current year.

Insider Activity at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan bought 1,250 shares of the stock in a transaction on Friday, June 14th. The shares were bought at an average cost of $20.03 per share, for a total transaction of $25,037.50. Following the completion of the transaction, the chief financial officer now owns 52,623 shares of the company’s stock, valued at approximately $1,054,038.69. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.10% of the company’s stock.

Institutional Trading of Syndax Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in shares of Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after buying an additional 1,150 shares in the last quarter. Iron Triangle Partners LP acquired a new stake in Syndax Pharmaceuticals in the 1st quarter valued at about $23,159,000. Janus Henderson Group PLC increased its holdings in Syndax Pharmaceuticals by 85.1% during the 1st quarter. Janus Henderson Group PLC now owns 48,948 shares of the company’s stock valued at $1,164,000 after acquiring an additional 22,501 shares in the last quarter. Kingdon Capital Management L.L.C. raised its position in Syndax Pharmaceuticals by 19.9% during the first quarter. Kingdon Capital Management L.L.C. now owns 894,993 shares of the company’s stock worth $21,301,000 after acquiring an additional 148,700 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Syndax Pharmaceuticals by 69.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 44,510 shares of the company’s stock worth $1,060,000 after acquiring an additional 18,243 shares during the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).